web analytics
10.3 C
Munich
Sunday, September 25, 2022

3 Stocks on the Move: Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN), CorMedix Inc. (NYSEMKT:CRMD), 22nd Century Group Inc (NYSEMKT:XXII)

Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN) recently made a spectacular move up off its base at $0.25 to highs of $2.58 after the Company announced its financial and operational results for the quarter ended December 31, 2014.

Results were nothing short of extraordinary with AXN reporting revenues in the second quarter increased 85% year over year to $6.4 million while cost of sales decreased 20% year over year to $1.6 million. Gross profit for the second quarter was $4.8 million, representing a 75% gross margin, and an increase of 233% as compared to the same quarter last year.

Net profit for the second quarter was $0.6 million instead of a net loss of $1.9 million for the same quarter last year and Net cash generated from operating activities for the six months ended December 31, 2014 was $3.4 million compared to the use of $2.8 million cash in operations for the period ended December 31, 2013. Basic and diluted income per common share were both $0.01 for the second quarter as compared to net loss of ($0.04) per basic and diluted share for the same quarter last year.

CEO Zhenjiang Yue said, “I am very pleased with Aoxing Pharma’s operating results this quarter, as our efforts and investment in building our own sales team last year start to payoff. We now have better coverage and penetration into hospitals and will continue to capture profit from our direct sales strategy. We plan to leverage our existing sales platform and bring on new products in the near term.”

22nd Century Group Inc (NYSEMKT:XXII) made a spectacular move up last year from pennies to a high of $6.36 before months of decline took the stock to recent lows of $0.65. Since then XXII has reversed and has been moving up steadily since recently surpassing $1 a share.

Back in January the Company said its wholly-owned subsidiary, NASCO Products, LLC, a federally licensed tobacco product manufacturer and participating member of the tobacco Master Settlement Agreement (MSA), made its first shipment of Smoker Friendly private label cigarettes.

We have a Monster Pick Coming. Subscribe Right Now!

Currently, Smoker Friendly has more than 800 stores throughout the United States under license. These stores are independently owned and operated. The “SF” brand has been on the market for over 20 years and is the private label brand in Smoker Friendly stores.

Pursuant to a multi-year manufacturing agreement the Company signed with Smoker Friendly International, LLC last August, and following the approval of that agreement by the 46 Settling States, the District of Columbia, and 5 U.S. territories under the MSA, effective as of January 2015, NASCO is Smoker Friendly International’s exclusive manufacturer of “SF” brand cigarettes.

CorMedix Inc. (NYSEMKT:CRMD) is making the kind of spectacular move up that we love to report on here; over the past 3 years the stock has transformed from illiquid at pennies to one of the top running stocks on the NYSE with recent highs of $7.76.

The move on CRMD comes as the U.S. Food and Drug Administration (FDA) has designated the company’s lead product candidate, Neutrolin® Catheter Lock Solution, as a Qualified Infectious Disease Product (QIDP) for oncology, hemodialysis and intensive care unit patients, where catheter-related blood stream infections and clotting can be life-threatening.

We have a Monster Pick Coming. Subscribe Right Now!

The QIDP designation will make Neutrolin eligible to benefit from certain incentives as provided under the Generating Antibiotic Incentives Now (GAIN) program. These incentives include FDA priority review, eligibility for fast-track status and, if ultimately approved by the FDA, Neutrolin would be eligible for an additional five-year extension of Hatch-Waxman patent exclusivity.

Disclosure: we hold no position in AXN, XXII or CRMD either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.